Wednesday, 1 July 2020

Coma Diagnosis & Treatment Market Strategies And Competitive Analysis, Forecast Till 2023

Market Scenario
Coma refers to a state of unconsciousness in which a patient remains unresponsive to anything around them for a prolonged period of time. Depending on the severity of the coma, patient may require life-saving resuscitative measures and once the patient is medically stable, treatments can be used to treat original problem that is causing the coma.
There is no particular treatment that can cause someone to come out of a coma and treatments can prevent further physical and neurological damage. However depending on the cause of a coma, patient who are continuosly in this state for more than one year are extremely unlikely to awaken.
Increasing prevalence of neurological disorders, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the Coma Diagnosis and Treatment Market. Moreover, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases will fuel the market growth during the forecast period
Over the last decade, the number of hospitals has increased to a great extent, which has influenced the growth of the market positively. Moreover, increasing demand for better treatment and changing reimbursement policies have fueled the market growth.
According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.
However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.
The global coma diagnosis & treatment market is expected to grow at a CAGR of ~7.1% during the forecast period 2017-2023. 
Key Players
  • GE Healthcare (U.S.)
  • Siemens Healthcare(U.S.)
  • Philips Healthcare (U.S.)
  • Carestream Health (U.S.)
  • Electrical Geodesics Inc. (U.S.)
  • Masimo Corporation (U.S.)
  • Hologic (U.S.)
  • Shimadzu Corporation (Japan)
  • Toshiba Medical Systems Corporation (Japan)
  • Fujifilm Holdings (Japan)
  • Nihon Kohden Corporation (Japan)
  • Esaote (Italy)

Regional Analysis
Asia Pacific is the fastest growing coma diagnosis & treatment market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.  
The Americas dominate the global coma diagnosis & treatment market owing to well-developed technology, increasing patient population for brain disorder, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Europe holds the second position in the global coma diagnosis & treatment market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.     
Segmentations
The global coma diagnosis & treatment market is segmented on the basis of types, diagnosis, treatment, and end user.
On the basis of diagnosis it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG).
On the basis of the type, it is segmented into toxic- metabolic encephalopathy, anoxic brain injury, persistent vegetative state, locked-in syndrome, and brain death.  
On the basis of treatment it is segmented into medical treatment, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.
Posted by at No comments:

Connective Tissue Disease Market Opportunities, Drivers, Manufacturers, Analysis And Forecasts Till 2023

Connective Tissue Disease Market Research Report information: Diagnosis (X-ray Examination, Antinuclear Antibody Test, Treatment (Non-Steroidal Anti-Inflammatory, Cortisone/Steroids, Antimalarial, Cytotoxic Drugs), End User - Global forecast till 2023
Connective tissues are a group of cellular congregations that provide support and structure to the human body. Connective tissue disease is a group of disorders which involves these protein rich tissues. Protein rich tissues play an important role of supporting organs and other parts of the body. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels. More than 200 disorders affect the connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.
Developments in the treatment of connective tissue diseases (CTDs) have been improved considerably, and the global connective tissue disease market is slated to grow at a promising CAGR of 11.5% over the forecast period of 2017-2023. The cause of the disease is unknown and there's no cure for connective tissue disease yet, but medications are present to manage the signs and symptoms. CTDs include a large number of disorders which can affect different organs of the body. There is broad variability in disorders among patient suffering from CTDs.
It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.
A significant increase in the research and development efforts to find treatment and cure for CTDs have aided the growth of the market. Various therapy trials are underway which have been able to identify promising novel approaches to treat CTDs and are expected to boost the growth of the market. Rising prevalence of CTDs across the globe, especially in women has propelled the growth of the market. Additionally, support from governments across the world along with funds for R&D from the private industry is also a key driver of the growth of the market. With the increase in awareness and acceptance among the general population about connective tissue diseases, the diagnosed and drug-treated population will increase which will positively impact the market. Rising expenditure on healthcare, high unmet medical needs of the current treatment and growing prevalence of CTDs in Asia and Africa are expected to promote the growth of the market.  However, the growth of the market might be hindered by lack of a knowledgeable workforce, inadequate research and development infrastructure, lack of funds in middle and low-income countries.
Key Players
Some of key the players in the market are
  • Abbott Laboratories
  • Bayer AG
  • Hoffmann-La Roche Ltd
  • Pfizer
  • AutoImmune Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • Biogen
  • LUPIN
Segmentation
The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.
On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others
On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.
Regional Analysis
The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.
Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.
Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities. 
Posted by at No comments:

Global Neurostimulation Devices Market Solid Segment Analyzed By Latest Trends, Growth Rate And 2023 Insight

Market Scenario:
Neurostimulation is a modulation of the nervous system’s activity. It is deliberately carried out by using invasive and non-invasive techniques. Implantable stimulation devices are most commonly used in the treatment of the neurological conditions such as epilepsy, Parkinson’s disease, dystonia, tremors, depression, obsessive compulsive disorder, diabetic neuropathy and few other conditions. Increasing cases of the neurological disorders such as chronic pain and depression high adoption of the Neurostimulation therapy are likely to improve the market of Neurostimulation devices. Globally, this Neurostimulation Devices Market Size is growing steadily and it is anticipated to show an exponential growth reaching approximately $11.5 billion in 2022
Segments:
Global Neurostimulation devices market has been segmented on the basis of type which comprises implantable devices, and external devices. Implantable devices include deep brain stimulators, spinal cord stimulators, sacral nerve stimulators, gastric electric stimulators, cochlear implants, and vagus nerve stimulators; whereas external devices include transcutaneous electrical nerve stimulator, and transcranial magnetic stimulator. On the basis of application, the market is segmented into dystonia, epilepsy, Parkinson's disease, depression, gastroparesis, pain management, tremors, urinary and fecal incontinence, and others. On the basis of end user, market is segmented into hospitals/clinics, cognitive care centers, research institutes and others.
Regional Analysis of Neurostimulation devices Market:
Considering the global scenario of the market, Americas region is believed to be the largest market for Neurostimulation devices. Moreover, the European market is also growing continuously and slowly catching up with the American market. On the other hand, Asia-Pacific market is expected to grow at the fastest pace in the Neurostimulation devices segment during the forecast period. Middle East & Africa region are likely to have a limited but steady growth in the market.
Key Players for Neurostimulation devices Market:                                     
Some of the key players in this market are: Autonomic Technologies, Boston Scientific, ElectroCore, ImThera Medical, Inspire Medical Systems, LivaNova (Cyberonics), Medtronic, NeuroMetrix, NeuroPace, Neuros Medical, NeuroSigma, Nevro Corporation, SPR Therapeutics, St.Jude Medical, Synapse Biomedical, and others.    
Regional Market Summary 
Geographically, the Americas is anticipated to dominate the global Neurostimulation Devices market owing to the rising prevalence of the cardiovascular diseases such as cardiac arrhythmia, arterial blockage, and coronary artery disease among others. The development of the better therapeutic approaches and advanced treatment procedures have affected the growth of the American market in a positive way.
According to the data published by the Department of Health, New York in May 2018, percutaneous coronary intervention is one of the two most common procedures performed on patients with coronary artery disease. Besides this, the high medical awareness among American population, high disposable income, presence of the top medical device manufacturers in the region are some of the many factors that drive the growth of the Neurostimulation Devices market in this region.
Europe is expected to hold the second largest market share in the global Neurostimulation Devices market. The market growth in this region is majorly attributed to the increasing government support for the device manufacturers. Geographical expansion of companies has led to the wider reach of the medical products and services which has brought a huge change in terms of the acceptance and implementation of the new products as well as procedures. Similarly, Asia-Pacific region has observed a rapid growth in the Neurostimulation Devices market owing to the development in the medical sector in developing countries like India and China. Moreover, increase in government funding for healthcare, rising R&D expenditure, and growing number of medical device companies in the region has led to its fastest growth during the forecast period. The Middle East and Africa region is anticipated to show minor growth opportunities in the Neurostimulation Devices market during the forecast period.
Posted by at No comments:

Worldwide Stroke Disorder & Treatment Market Ready To Set Outstanding Growth From 2019 To 2023

Stroke disorders are an array of disorders caused by strokes. High stress levels, alcoholism, and other factors are accountable for maximum number of stroke cases. The global stroke & disorder treatment report by Market Research Future (MRFR) contains drivers and challenges to be faced by industry leaders for the period of 2016 to 2022 (forecast period). It also takes into consideration the impact of COVID-19 on market dynamics.
Stroke Disorder & Treatment Market Outlook
The global stroke disorder treatment market is predicted to scale during the forecast period owing to the rise in the number of cases of cardiovascular diseases, diabetes, and others. Rising prevalence of chronic disorders can fuel the market demand. The large geriatric populace susceptible to strokes owing to their age and weak immune system can create demand in the market.
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/1651
Awareness of strokes is expected to augur favorably for the market. Public awareness campaigns endorsed by celebrities and recognizable celebrities can lead to huge amount of testing.  Initiatives to train doctors for improving the outcomes of heart surgeries are expected to drive the market growth. The introduction of mobile stroke units in hospitals is a positive step in the market. Furthermore, the COVID-19 pandemic is showing strokes in patients between the ages of 30 and 40 furthering the market prospects.
But high costs of treatment and lengthy process for approval of devices and equipment can hamper market growth.
Stroke Disorder & Treatment Market Segmentation
The global stroke disorder & treatment market has been segmented by type, medicine, and treatment.
By type, it is divided into ischemic stroke and hemorrhagic stroke. Ischemic strokes are expected to lead in the global market due to rise in these cases.
Medicines produced in the market are of 2 types, anticoagulants/antiplatelet and anti-hypertensive. Anticoagulants are blood thinners which prevent the thickness of blood which can cause clots. Some drugs able to prevent strokes include warfarin, Apixaban, edoxaban, dabigatran, rivaroxaban, heparin, and enoxaparin. Antihypertensives are a drug class able to treat high blood pressure.
By treatment, the market includes endovascular procedures, carotid endarterectomy, tissue plasminogen activator (TPA), surgical treatment, and others. The endovascular procedures segment is projected to perform exceptionally during the forecast period owing to being minimally invasive in nature. It is used in the treatment of aneurysms.
Stroke Disorder & Treatment Market Regional Analysis
Europe, North America, Asia Pacific (APAC), and Rest-of-the-World (RoW) are regions covered in the global stroke disorder treatment market.
North America is expected to register high revenue for the global market due to the large number of cases of strokes and investments in advanced medical facilities. According to the American Medical Association, the geriatric pool of patients in the U.S. is susceptible to strokes. Presence of prominent names and launch of continuous products can fuel the market growth to new heights.
Europe is projected to show maximum growth owing to inclination towards minimally invasive treatments and encouragement of new techniques. The use of artificial intelligence to improve the outcomes of surgeries is a positive step in stroke treatment.
APAC is expected to display a stellar growth rate owing to establishment of facilities to handle strokes. Adoption of portable devices to resuscitate patients in ambulances as well as hiring of skilled specialists can drive the regional market. Improvements in healthcare infrastructure as well as the continuous growth of developing economies can bode well for the market.
Stroke Disorder & Treatment Market Competition Outlook
Pfizer, Novartis AG, Daiichi Sankyo, AstraZeneca, Bayer Pharma AG, and others are key players of the global stroke disorder treatment market.
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/stroke-disorder-treatment-market-1651
Posted by at No comments:

Global Cerebral Vasospasm Market Set For Big Growth - Foresight By 2023

Global Cerebral Vasospasm Market - Scenario
The advances in medical knowledge are leading to the breakthroughs being achieved in the treatment of cerebral vasospasm. Reports that examine the medical device industry has been presented by Market Research Future, which produces reports on industry verticals that evaluate the market development and opportunities. The market is expected to gain a CAGR of 5.4 % in the upcoming period.
Cerebral vasospasm is most commonly observed in patients who survive subarachnoid hemorrhage. The narrowing of cerebral arteries is termed as cerebral vasospasm. Narrowing of cerebral artery leads to cerebral ischemia and then death. Increasing prevalence of subarachnoid hemorrhage and a rise in the prevalence of traumatic brain injury is the key factor driving the growth of the market.  According to the Centers for Disease Control and Prevention 2017, 30% of the total injury deaths are due to traumatic brain injury in the US. Other factors contributing to the growth of the market are increasing hypertension among the population, rising adoption of smoking, changing lifestyle, growing geriatric population, increasing prevalence of bleeding disorders, rising use of blood thinners and the introduction of technologically advanced treatments.
However, factors such as high cost associated with treatment, risks associated with drugs and medication and a shortage of skilled professionals are expected to hinder the market growth during the forecast period.
Segmentation
Global cerebral vasospasm market is segmented on the basis of type of treatment which includes triple-H therapy, nimodipine and other. On the basis of route of administration the market is segmented into oral, intravenous and intra-arterial and on the basis of end user the market is again segmented into hospitals, clinics and others.
Key Players
  • Headsense Medical Ltd (Israel),
  • Braun Melsungen AG (Germany),
  • Minnetronix, Inc (US),
  • Bristol-Myers Squibb Company (US),
  • Boehringer Ingelheim GmbH (Germany)  
  • Lundbeck A/S (Denmark)
Regional Analysis                                                                                
Geographically, North America has the largest market of cerebral vasospasm. North America cerebral vasospasm market is driven by robust research & development practices along with growing advancements in the field of neurology. Europe has the second largest market of cerebral vasospasm which is followed by Asia Pacific. In Middle East and Africa the market is least due to limited development in the healthcare sector. 
The report of global cerebral vasospasm market by Market Research Future comprises of extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts and key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the market’s different segments and regions.
Posted by at No comments:

Enema Bags Market Report By Global Industry Trends And Forecast The Upcoming Opportunities And Demand Till 2023

Global Enema Bags Market Research Report: Information by Material Type (Silicone, Rubber, and Others), Indication (Constipation, Diarrhea, Obesity, Cancer, and Others), End User (Hospitals & Clinics, Research & Academic Institutes, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2025
Market Scenario:
Some health problems due to unhealthy eating, drinking in lifestyle may not be fatal but they can a hard time to the body they occur in. One such problem is constipation. A common remedy for constipation is an enema. Apart from constipation, enema provides relief from backaches, fatigue, and headaches. A cleansing enema stimulates the bowels to expel any impacted fecal matter quickly. A remedy helpful for many health problems always grows rapidly as a market. The factors driving the market growth include rising chronic diseases in an aging population with cancer and diabetes coupled with the increasing prevalence of gastrointestinal disorders and growing awareness about enema administration. Home care is advisable to be administered only after the advice of the clinician. Factors that can cause roadblocks to the growth of global enema bags market include the possibility of newer methods of enema treatment and environmental concerns raised from the bags that are made up of silicone, rubber, etc.
Enema is the process of injecting fluid into the bowel via the rectum. This method is used to get relief from various conditions such as constipation, fatigue, headaches, and backaches. It is a process that helps to push out the waste from the rectum. A cleansing enema stimulates the bowels to expel any impacted fecal matter quickly.
The Global Enema Bag Industry Market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global enema bags market is expected to register a CAGR of ~ 10.2 % during the forecast period of 2018–2023.
Enema can be administered at hospitals as well as in home. This technique is also preferred before performing bowel procedures such as radiography and colonoscopy. The most common gastrointestinal condition affecting people nowadays is constipation with the ever-rising prevalence across the globe. Furthermore, the use of enema based products for bowel cleansing is growing extensively.
However, certain disrupting factors that might restrain the growth of enema bags include the possibility of newer methods of enema treatment. Moreover, there might be environmental issues as the bags are made up of silicone, rubber, etc.
Segmentation
The global enema bags market is segmented on the basis of the material type, product type, application, capacity, and end-user.
On the basis of material type, the market is classified into silicone, rubber, and others.
On the basis of administration type, the market is segmented into cleansing enema, carminative enema, retention enema, return-flow enema, and others. Cleansing enema is further segmented into large volume enema, small volume enema, and prepackaged disposable enema. Retention enema is further segmented into oil enema, sedative enema, nutrient enema, anesthetic enema, medicinal enema, and others.
The global enema bags market on the basis of product type is segmented into closed or bottle enema, Higginson enema, bulb enema, bag or fountain travel enema, and others.
On the basis of indication, the market is segmented into constipation, diarrhea, obesity, cancer, and others.
On the basis of preparation, the market is divided into sodium phosphate enemas, coffee enemas, barium enemas, water-soluble contrast enemas, and others. Barium enemas are further segmented into single-column barium enema and double-contrast barium enema.
On the basis of application, the market is segmented as bowel clearing, contrast x-ray, medication administration, and others.
On the basis of capacity, the market is segmented into 100 to 250 ml, 250 to 400 ml, 400 to 600 ml, and others.
On the basis of end-user, the global enema bags market is segmented into hospitals, clinics, research centers, and others.
Geographically, the market has been segmented into America, Europe, Asia Pacific, and the Middle East and Africa. The American enema bags market is further segmented into North America and South America. North America is further classified as the U.S. and Canada.
The European enema bags market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the U.K., Italy, Spain, and the rest of Western Europe. 
The Asia Pacific enema bags market is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia Pacific.
The Middle Eastern and African enema bags market is segmented into the Middle East and Africa.
Top Key Players             
The key players in global enema bags market are Baxter International, Inc. (the USA), B Braun Melsungen AG (Germany),  Cascade Healthcare Products, Inc. (the USA), Coloplast A/S (Denmark), Covidien Private Ltd. (Ireland), Farla Medical Ltd. (UK), Flexicare Medical Limited (UK), Hollister Incorporated (USA), MacoPharma (France), Medline Industries, Inc. (USA), Narang Medical Ltd. (India), Ocean Health Products Ltd. (Singapore), and Qingdao Sinoland International Trade Co., Ltd. (China).
Regional Market Summary
Globally, the American region is the largest market for enema bags owing to the high level of hygiene developed in hospitals and clinics, increasing use of enema-based products at home, and rising demand for enema kits by healthcare providers. As per a study conducted by the Canadian Journal of Gastroenterology, constipation is a common problem among the people in the North American region. Moreover, the study stated that 20% of the North American population suffers from constipation.
Asia Pacific and North America are expected to collectively dominate the enema bags market in terms of volume and value, respectively, due to the increase in awareness towards abdominal diseases and high demand from the pharmaceutical and healthcare industry. The U.S. has the largest market of enema bags in the North American region and countries such as India and China are the highest producers of enema bags in the Asia Pacific region. The factor influencing the growth is the increasing prevalence of chronic diseases such as obesity and diabetes. Currently, the major problem in China and India is diabetes. India had the world’s second-largest population of diabetic patients that was around 69.2 million in 2015 which is expected to increase to 123.5 million by 2040. The number of undiagnosed diabetes is higher in India which was around 36 million in 2015.
The European market is growing due to the increasing prevalence of diarrhea, obesity, and constipation. Increasing cases of enema administration procedures in hospitals are contributing to the progress of the market. The prevalence of diabetes is also found to be increasing in Europe. As per a study published by the World Health Organization, almost 60 million people in the European region have diabetes, and the prevalence tends to be high among people aging 30 years and above.
The Middle East and Africa also shows a steady rise in the market owing to the availability of enema-based products, lack of physical exercise, and increasing cases of constipation.
Posted by at No comments:

Global Cardiovascular Needle Market Production, Capacity, Revenue, Price, Gross Margin Analysis And Forecast 2019-2023

Cardiovascular Needle Market Information: By Type (Round-Bodied Needles, Cutting Needles), By Application (Open Heart Surgery, Cardiac Valve Procedures), By Usage (Single Use, Multiple Uses), By End User (Hospitals, Clinics) - Global Forecast till 2023
Market Insights:
According to the International Diabetes Federation in 2016, it was estimated that 420 million adult population had diabetes, which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. Furthermore, increasing prevalence of population suffering from cardiovascular diseases, diabetes, and obesity driving the growth of the cardiovascular needles market globally.
The global cardiovascular needles market is growing rapidly owing to its application in various fields such as open heart surgery, cardiac valve procedures, coronary artery bypass graft surgery, heart transplant, and others.
According to the World Health Organization (WHO) in 2015, around 1.6 million deaths were directly caused by diabetes and in 2014, 8.5% of adults aged 18 years and older had diabetes. Thus, rising prevalence of chronic diseases is majorly driving the global cardiovascular market.
According to the World Health Organization (WHO), in 2015, around 17.7 million people died from cardiovascular diseases, which represents 31% of all global deaths. Of these deaths, around 7.4 million were due to coronary heart disease and 6.7 million were due to stroke.
Various factors are adding fuel to the growth of the global cardiovascular needle market, such as unhealthy diet, low physical activities, etc. According to a research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the market.
Moreover, advancing technology in the medical devices is adding fuel to the growth of the market. Furthermore, increasing government support in the developing countries drive the market growth.
However, increasing use of surgical staples instead of needles and suture can deter the demand for cardiovascular needles.
The global cardiovascular needle market is expected to grow at a CAGR of 7.2% during the forecast period 2017-2023.
Key Players
Some of the key the players in the market are Becton, Dickinson, and Company (US), B. Braun Melsungen AG (Germany), Sheffield Ltd. (UK), CP Medical, Inc. (the US), Ethicon Inc. (US), KLS Martin Group (US), Sklar Surgical Instruments (US), Rumex International Corporation Ltd. (US), Scanlan International Inc. (US), Teleflex Incorporated (US), Medline Industries, Inc. (US), Surgins surgical Ltd. (UK), Surtex Instruments Ltd. (UK), Cardivon Surgical Inc. (China), Symmetry Surgical Inc. (US), Delacroix-Chevalier (France), Wexler Surgical (US), Quality Needles Pvt. Ltd. (India), FSSB surgical needles GmbH (Germany)
Segmentations
The global cardiovascular needle market is segmented on the basis of types, by application, by usage, and by the end user.
On the basis of the type, it is segmented into round bodied needles and cutting needles. Furthermore, round-bodied needles segmented into taper point needles and blunt point needles. Also, cutting needles segmented into conventional cutting needles and reverse cutting needles.  
On the basis of the application, it is segmented into open heart surgery, cardiac valve procedures, coronary artery bypass graft surgery, heart transplant, and others.  
On the basis of the usage, it is segmented into single use and multiple uses.
On the basis of the end user, it is segmented into hospitals, clinics, ambulatory surgical centers, and others.
Regional Analysis
The Americas dominate the global cardiovascular needle market owing to the rising prevalence of diabetes, obesity, and cardiovascular diseases. Furthermore increasing government support for research & development have fuelled the growth of the market in this region. According to the American Heart Association, in 2017, cardiovascular disease listed as the underlying cause of death which is likely to account for nearly 801,000 deaths in the US by the end of this year. It further estimated that about 2,200 Americans die of cardiovascular disease each day.
Europe holds the second position in the global cardiovascular needle market owing to the presence of major players. Although companies within this region are also involved in export to the developing countries which leads the market of Europe.
The Asia Pacific is the fastest growing Cardiovascular Needle market owing to the high presence of a patient with cardiovascular disease. Furthermore, the government of this region is looking forward to better the quality of needles, which increases the demand for cardiovascular needle market in this region.
On the other hand, in the Middle East and Africa hold the least market due to low research and development activities and poor healthcare infrastructure.
Posted by at No comments:
Subscribe to: Posts (Atom)